Pilot project exercise (UQAM)
Optimizing exercise prescription for prostate cancer patients: a pilot study based on participant preferences Nature et objective :A challenge for health professionals is to find adjuvant therapies with a low level of toxicity to combine with standard treatments in order to alleviate the burden of treatment in patients with prostate cancer. Physical activity (PA) is interesting, […]
PAnTHA
A Phase 1 open-label, first-in-human, multi-center study to evaluate the safety, tolerability, pharmacokinetics, and antitumor activity of 225Ac-PSMA-Trillium in participants with advanced metastatic castration-resistant prostate cancer (mCRPC) Nature and objective :The PAnTHA study aims to assess the safety, tolerance, pharmacokinetics, and preliminary efficacy of 225Ac-PSMA-Trillium, a targeted alpha therapy that is a new class of […]
MK-5684-003
Phase 3, Randomized, Open-Label Trial of MK-5684 Versus Abiraterone Acetate or Enzalutamide in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC) Previously Treated With a next-generation hormonal agent (NHA) and taxane-based chemotherapy. (MK-5684-003) Nature et objective:This trial is testing MK-5864 in men with metastatic castration-resistant prostate cancer (mCRPC). This trial will compare MK-5684 to abiraterone acetate […]
